CALGARY – SemBioSys Genetics Inc. (TSX:SBS) said Tuesday it has signed an agreement with one of China’s largest pharmaceutical companies to sell its plant-based manufacturing technology.
The Calgary company said it has a joint venture agreement with Tasly Pharmaceuticals Ltd. under which SemBioSys will be entitled to 30 per cent ownership and profit sharing.
Get weekly money news
Tasly will contribute 100 per cent of the cost of the joint venture’s global research, development and product commercialization.
The new company created under the joint venture deal will develop and commercialize a variety of products for China and around the world.
SemBioSys is a biotechnology company develops high value proteins and oils and drug candidates for health and wellness products.
Tasly is China’s second largest producer of traditional Chinese medicines derived from plants.
Comments
Want to discuss? Please read our Commenting Policy first.